This inventor holds 1 USPTO granted patent and 1 published patent application, plus 1 CIPO patent and 1 EPO patent. Top assignee: Wilex Ag. Active years: 2017.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2017
Title: Egbert Oosterwijk: Innovator in Monoclonal Antibody Production
Introduction
Egbert Oosterwijk is a notable inventor based in Beuningen, Netherlands. He has made significant contributions to the field of biotechnology, particularly in the production of monoclonal antibodies. His work has implications for medical research and therapeutic applications.
Latest Patents
Oosterwijk holds a patent for a hybridoma cell line known as G250. This invention is crucial as it enables the production of the monoclonal antibody G250. The patent also details methods for utilizing this cell line to manufacture G250 and its derivatives, including chimeric and humanized antibodies.
Career Highlights
Oosterwijk is associated with Wilex AG, a company that focuses on developing innovative cancer therapies. His role at Wilex AG has allowed him to further his research and contribute to advancements in monoclonal antibody technology.
Collaborations
Throughout his career, Oosterwijk has collaborated with notable colleagues such as Sven Warnaar and Stefan Ullrich. These collaborations have enhanced his research efforts and expanded the impact of his inventions.
Conclusion
Egbert Oosterwijk's work in developing the hybridoma cell line G250 represents a significant advancement in the field of monoclonal antibodies. His contributions continue to influence medical research and therapeutic development.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile